KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.

N Engl J Med · 2025-Jun-26 · PMID 40444708

Panel Panel_A提取完成待 EXE 对齐验证

Overall Survival

Figure 2.. Analysis of Overall Survival. Panel A shows Kaplan–Meier estimates of overall survival in the EC, EC+mFOLFOX6 and SOC. Panel B shows a forest plot of the analyses in pre-specified subgroups in the EC+mFOLFOX6 and SOC arms. Because the result of the interim analysis of overall survival was statistically significant, no further statistical test will be performed. *Analyses of EC versus SOC and EC versus EC+mFOLFOX6 are descriptive. CIs are not adjusted for multiplicity and should not be mistaken for hypothesis tests. Following a protocol amendment, enrollment into the EC arm was discontinued prematurely. † Subgroup analyses are exploratory and descriptive in nature; CIs are not adjusted for multiplicity and should not be interpreted as hypothesis tests. CI, confidence interval; EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU; HR, hazard ratio; SOC, standard of care.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线3
实际曲线3
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证32026-07-16T16:57:35+00:00